Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Stiripentol - Biocodex

Drug Profile

Stiripentol - Biocodex

Alternative Names: BCX 2600; Diacomit; ME-2080

Latest Information Update: 27 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biocodex
  • Developer Biocodex; Meiji Seika Pharma
  • Class Antiepileptic drugs; Dioxolanes; Neuroprotectants
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myoclonic epilepsies
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myoclonic epilepsies

Most Recent Events

  • 01 Feb 2019 Biocodex plans a phase II trial for Hyperoxaluria (Monotherapy) (NCT03819647)
  • 23 Aug 2018 Biocodex intends to launch Stiripentol for Myoclonic epilepsies in USA in January 2019
  • 20 Aug 2018 Registered for Myoclonic epilepsies (Adjunctive treatment) in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top